Studies have reported that pairing the Met receptor aptamer with a cancer cell biomarker, CD71 or Transferrin receptor (TfR), using a bispecific aptamer interferes with the interaction between the Met receptor and hepatocyte growth factor (HGF), thereby inhibiting cancer cell metastasis [136,137]. The gene discussed is TFRC; the disease is cancer.